Csquare, Inc. (NYSE:CSQR) filed its third-quarter 2026 earnings disclosure on November 9, 2026, reporting revenue of $302.3 million, record bookings, and balance sheet changes following its July 2026 initial public offering.
The Generation Essentials Group filed an 8-K on November 9, 2026, announcing an extraordinary general meeting scheduled for December 7, 2026, at which shareholders will vote on a 15-for-1 share consolidation intended to help the company regain compliance with NYSE minimum average closing share …
National Health Investors, Inc. filed its third-quarter 2026 earnings disclosure on November 9, 2026, reporting results for the quarter ended September 30, 2026, highlighted by a $541.6 million gain on the sale of its National Healthcare Corporation leased portfolio.
Shutterstock, Inc. filed a definitive proxy statement on November 9, 2026, notifying stockholders of its 2026 Annual Meeting of Stockholders scheduled for December 22, 2026, at 10:00 a.m. Eastern Time via live webcast.
Jane Street Group, LLC filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 4,246,421 shares of AXT Inc common stock, representing 6.5% of the class, as of the triggering event date of November 3, 2026.
Xiaofeng Ma and affiliated entities filed Amendment No. 11 to a Schedule 13D with the SEC on November 9, 2026, disclosing updated beneficial ownership of Common Shares in ATA Creativity Global following the termination of Ma Family Trust on September 25, 2026.
Myriad Genetics, Inc. filed a Form 8-K on November 9, 2026, disclosing that its Compensation and Human Capital Committee approved one-time retention stock option awards for three named executive officers on November 6, 2026.
Goosehead Insurance, Inc. filed a Form 8-K on November 9, 2026, disclosing that its Audit Committee determined previously issued financial statements for fiscal years 2023 through 2026 interim periods should no longer be relied upon and must be restated.
Aldeyra Therapeutics, Inc. filed a Form 8-K on November 9, 2026, disclosing that it has formally requested a review jurisdiction transfer for its ADX-2191 Investigational New Drug application and has withdrawn the previously agreed Special Protocol Assessment protocol for the treatment of primary vitreoretinal …
Lantronix, Inc. filed a current report on November 9, 2026, disclosing its financial results for the first fiscal quarter ended September 30, 2026, alongside a transcript of management's prepared remarks for the accompanying investor conference call.